Tirzepatide
The dual-receptor incretin agonist positioned between single-target Semaglutide and triple-target Retatrutide — adding GIP receptor activity on top of the GLP-1 mechanism the whole drug class started from.
Not available from KYIN Peptides. Tirzepatide is a patented, FDA-approved prescription pharmaceutical — it is covered here purely for research and educational context.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Where Semaglutide activates the GLP-1 receptor alone, tirzepatide adds GIP receptor activity on top of it — and research suggests it actually engages the GIP receptor more strongly than the GLP-1 receptor, which is thought to contribute to its stronger weight-loss results and, in some studies, fewer gastrointestinal side effects relative to single-target GLP-1 agonists.
Regulatory & Brand History
Tirzepatide received FDA approval as Mounjaro in 2022 for type 2 diabetes, followed by approval as Zepbound in 2023 specifically for chronic weight management. Both are prescription-only pharmaceutical products.
Research Focus
Tirzepatide is referenced constantly in comparative incretin-receptor literature alongside Retatrutide and Semaglutide. See our Weight Loss & Metabolic research overview, or the full Semaglutide vs Tirzepatide vs Retatrutide comparison for how the three mechanisms and trial results stack up directly.
Clinical Trial Data
The Phase 3 SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022; 2,539 adults with obesity or overweight, without diabetes) reported 16.0–22.5% mean weight loss across the 5mg/10mg/15mg doses over 72 weeks. A later head-to-head trial, SURMOUNT-5, found tirzepatide outperformed semaglutide directly — 20.2% versus 13.7% mean weight loss.
Availability
Tirzepatide is not available from KYIN Peptides in any form. It is a patented, prescription-only pharmaceutical product requiring a doctor's prescription, not a research chemical sourced through peptide suppliers.
Tirzepatide questions
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Research suggests it engages the GIP receptor more strongly than the GLP-1 receptor, which is thought to contribute to its stronger weight-loss results and, in some studies, fewer gastrointestinal side effects compared to single-target GLP-1 agonists like semaglutide.
Does KYIN Peptides sell Tirzepatide?
No. Tirzepatide is a patented, FDA-approved prescription pharmaceutical product, marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), and is not part of our catalogue. This page provides educational and research context only.
How does Tirzepatide compare to Semaglutide or Retatrutide?
Tirzepatide adds GIP receptor activity on top of the GLP-1 activity semaglutide targets alone (a dual agonist). Retatrutide goes a step further, adding glucagon receptor activity on top of both (a triple agonist). In a head-to-head trial (SURMOUNT-5), tirzepatide outperformed semaglutide directly — 20.2% versus 13.7% mean weight loss.
Looking for a compound KYIN actually supplies?
See Retatrutide, the triple-receptor agonist in our catalogue.